Table 1.
Demographic characteristics at the time of transplantation
| No induction | rATG | Basiliximab | P-value | ||||
|---|---|---|---|---|---|---|---|
| Number |
25 |
|
28 |
|
18 |
|
|
| Gender (male/female) |
14/11 |
|
19/9 |
|
9/9 |
|
n.s.b |
| Recipient age (years) |
57,9 |
[27.7; 73.3] |
52,9 |
[21.5; 78.6] |
52,9 |
[25.6; 67.1] |
n.s.d |
| Donor age (years) |
52.0 |
[16.0; 68.0] |
46.5 |
[22.0; 74.0] |
63.5 |
[46.0; 75.0] |
<0.001d,e |
|
aHLA MM |
3 |
[1; 6] |
|
[2; 5] |
|
[1; 5] |
n.s.d |
| 1st/2nd and 3rd T x R (n) |
25/0 |
|
12/16 |
|
18/0 |
|
<0.0001b |
|
aPRA (%) |
4 |
[0; 36] |
64 |
[0; 96] |
7 |
[0; 44] |
<0.0001d,g |
|
aCNI (TAC/CsA)(n) |
21/4 |
|
28/0 |
|
18/0 |
|
n.s.b |
|
aCIT (hours) |
15.2 |
[11.0; 20.7] |
15.9 |
[7.7; 22.8] |
17.6 |
[12.4; 21.0] |
n.s.d |
| Dialysis time (years) |
2.0 |
[0.2; 9.42] |
2.2 |
[0.5; 6.37] |
2.1 |
[0; 4.9] |
n.s.d |
|
Cause of renal failure |
|
|
|
|
|
|
n.s. |
| Primary GN |
10 |
|
10 |
|
5 |
|
|
| Hereditary diseases |
4 |
|
6 |
|
6 |
|
|
| Diabetic or ischaemic nephropathy |
8 |
|
2 |
|
5 |
|
|
|
aTIN |
2 |
|
3 |
|
1 |
|
|
|
aANCA vasculitis or lupus nephritis |
0 |
|
4 |
|
0 |
|
|
| Other causes | 1 | 3 | 1 |
aANCA, anti-neutrophil cytoplasmic antibodies; CIT, cold ischaemic time; CNI, calcineurin inhibitor; CsA, cyclosporine A; GN, glomerulonephritis; HLA MM, HLA mismatch; PRA, historical panel reactive antibodies, measured every 3 months before transplantation, the highest number was considered in each patient; TAC, tacrolimus; TIN, tubulointerstitial nephritis; T 3, renal transplantation.
bChi square test P-value.
dKruskal–Wallis test P value.
eDunn’s multiple comparison test: significant difference between the basiliximab group and the rATG or controls.
gDunn’s multiple comparison test: significantp difference between rATG and the no induction or basiliximab groups.